Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients | Zendy

Stefan John | Zendy; Markus P. Schlaich | Zendy; Matthias Langenfeld | Zendy; H. Weihprecht | Zendy; Gerd Schmitz | Zendy; Gottfried Weidinger | Zendy; Roland E. Schmieder | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients

Author(s) -

Stefan John,

Markus P. Schlaich,

Matthias Langenfeld,

H. Weihprecht,

Gerd Schmitz,

Gottfried Weidinger,

Roland E. Schmieder

Publication year - 1998

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.98.3.211

Subject(s) - medicine , vasodilation , endothelium , fluvastatin , placebo , nitric oxide , omega n methylarginine , endocrinology , pharmacology , anesthesia , nitric oxide synthase , simvastatin , pathology , alternative medicine

Impaired endothelium-dependent vasodilation is an early sign of atherosclerosis in hypercholesterolemic patients. We hypothesized that lipid-lowering therapy can improve endothelial function and that this effect is mainly mediated by increased bioavailability of nitric oxide (NO).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research